Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | Zendy

Milton Packer | Zendy; Stefan D. Anker | Zendy; Javed Butler | Zendy; Gerasimos Filippatos | Zendy; Stuart J. Pocock | Zendy; Peter E. Carson | Zendy; James L. Januzzi | Zendy; Subodh Verma | Zendy; Hiroyuki Tsutsui | Zendy; Martina Brueckmann | Zendy; Waheed Jamal | Zendy; Karen Kimura | Zendy; Janet Schnee | Zendy; Cordula Zeller | Zendy; Daniel Cotton | Zendy; Edimar Alcides Bocchi | Zendy; Michael Böhm | Zendy; DongJu Choi | Zendy; Vijay Chopra | Zendy; Eduardo ChuquiureValenzuela | Zendy; Nadia Giannetti | Zendy; Stefan Janssens | Zendy; Jian Zhang | Zendy; José Ramón González–Juanatey | Zendy; Sanjay Kaul | Zendy; HansPeter BrunnerLa Rocca | Zendy; Béla Merkely | Zendy; Stephen J. Nicholls | Zendy; Sergio V. Perrone | Zendy; Ileana L. Piña | Zendy; Piotr Ponikowski | Zendy; Naveed Sattar | Zendy; Michele Senni | Zendy; MarieFrance Seronde | Zendy; Jindřich Špinar | Zendy; Iain Squire | Zendy; Stefano Taddei | Zendy; Christoph Wanner | Zendy; Faı̈ez Zannad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Author(s) -

Milton Packer,

Stefan D. Anker,

Javed Butler,

Gerasimos Filippatos,

Stuart J. Pocock,

Peter E. Carson,

James L. Januzzi,

Subodh Verma,

Hiroyuki Tsutsui,

Martina Brueckmann,

Waheed Jamal,

Karen Kimura,

Janet Schnee,

Cordula Zeller,

Daniel Cotton,

Edimar Alcides Bocchi,

Michael Böhm,

DongJu Choi,

Vijay Chopra,

Eduardo ChuquiureValenzuela,

Nadia Giannetti,

Stefan Janssens,

Jian Zhang,

José Ramón González–Juanatey,

Sanjay Kaul,

HansPeter BrunnerLa Rocca,

Béla Merkely,

Stephen J. Nicholls,

Sergio V. Perrone,

Ileana L. Piña,

Piotr Ponikowski,

Naveed Sattar,

Michele Senni,

MarieFrance Seronde,

Jindřich Špinar,

Iain Squire,

Stefano Taddei,

Christoph Wanner,

Faı̈ez Zannad

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2022190

Subject(s) - empagliflozin , heart failure , medicine , ejection fraction , cardiology , diabetes mellitus , benzhydryl compounds , broad spectrum , heart failure with preserved ejection fraction , type 2 diabetes , endocrinology , chemistry , organic chemistry , bisphenol a , epoxy , combinatorial chemistry

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research